A brief history of NEDA
Author:
Publisher
Elsevier BV
Subject
Clinical Neurology,Neurology,General Medicine
Reference14 articles.
1. Editors' welcome and a working definition for a multiple sclerosis cure;Banwell;Mult. Scler. Relat. Disord.,2013
2. Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study;Cook;Mult. Scler.,2011
3. Long-term evolution of multiple sclerosis disability in the treatment era;Cree;Ann. Neurol.,2016
4. De Sèze G. Giovannoni B. Hemmer K. Rammohan D. Masterman C. Bernasconi W. Wei S. Belachew P. Chin J. Wolinsky, X.M.D.L.A.A.B.-.O.J., 2016. Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial, In: ECTRIMS 2016. pp. 50–51.
5. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis;Giovannoni;Lancet Neurol.,2011
Cited by 41 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Predicting disease severity in multiple sclerosis using multimodal data and machine learning;Journal of Neurology;2023-12-22
2. Prevalence of 2-year “No evidence of disease activity” (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study;Multiple Sclerosis and Related Disorders;2023-11
3. A Preliminary Study on the Meaning of Inflammatory Indexes in MS: A Neda-Based Approach;Journal of Personalized Medicine;2023-10-26
4. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review];Neurology and Therapy;2023-10-11
5. Recommendations for the coordination of Neurology and Neuroradiology Departments in the management of patients with multiple sclerosis;Neurología (English Edition);2023-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3